---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-033055"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2024-07-26T23:59:59+00:00"
generated_at: "2026-05-31T16:06:59.013511+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)

## Summary
- GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
- Record adjusted EBITDA $62.3M (+5.0% YoY); cash from ops $45.0M; free cash flow $38.4M.
- Human Nutrition & Health and Specialty Products segments post strong sales and earnings growth.
- Launched Optifolin+ patented choline-enriched folate ingredient on May 20, 2024.
- Repaid $35M revolving debt; net debt $202.8M; leverage ratio 0.9x.

## SEC filing metadata
- accession: 0001628280-24-033055
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2024-07-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/0001628280-24-033055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000162828024033055/bcpc-20240726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-033055
- JSON: https://secwatch.observer/filing/0001628280-24-033055.json
- Plain text: https://secwatch.observer/filing/0001628280-24-033055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.